Proposed
Bill · 119th Congress · HR 1051
To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.
Refreshed 2 h ago
Introduced 2025-02-06Topic: health careSummary
No summary yet. The official text is available on Congress.gov.
Sponsors
- Nikki Budzinski Democrat sponsor
- 0 cosponsors
Action history
| Date | Chamber | Action | Status effect |
|---|---|---|---|
| 2025-02-06 | House | Referred to the House Committee on Energy and Commerce. | refer |
| 2025-02-06 | Introduced in House | introduce | |
| 2025-02-06 | Introduced in House | introduce |